Today, the standard of care involves C5 inhibitors. These monoclonal antibodies work by blocking the C5 protein in the complement cascade, effectively halting the immune system’s attack on blood vessels. These therapies have revolutionized the prognosis for aHUS patients, often allowing for the recovery of kidney function and preventing the need for long-term dialysis. Living with a Rare Disease
Complications of aHUS can include:
Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA) characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Unlike typical Shiga-toxin producing E. coli HUS (STEC-HUS), aHUS results from chronic, uncontrolled activation of the alternative complement pathway. This paper provides a comprehensive review of the genetic and acquired abnormalities leading to endothelial injury, the clinical spectrum from infancy to adulthood, diagnostic challenges in distinguishing aHUS from other TMAs, and the paradigm shift from plasma exchange to terminal complement inhibition with eculizumab and ravulizumab. We also explore emerging therapies targeting proximal complement components and the ongoing challenge of long-term management and transplantation. atypical hemolytic syndrome
Unlike "Typical" HUS, which is usually caused by an E. coli infection (often from contaminated food), aHUS is genetic and chronic . It is caused by a mutation that leads to uncontrolled activation of the complement system (a part of the immune system). Basically, the immune system mistakenly attacks the body's own healthy blood cells. Today, the standard of care involves C5 inhibitors